{
    "nctId": "NCT05806385",
    "briefTitle": "Grouping Immune-modulation With Cryoablation (LOGIC) for Breast Cancers",
    "officialTitle": "Local Therapy Optimization by Grouping Immune-modulation With Cryoablation (LOGIC) for High Risk Breast Cancers",
    "overallStatus": "NOT_YET_RECRUITING",
    "conditions": "Triple Negative Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1, PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 36,
    "primaryOutcomeMeasure": "Rate of Complete Pathological Response",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Females\n* Stage I/II Cancer\n* Age range 18 - 90 years\n* Diagnoses: Invasive carcinoma, ER -, PR-, HER2- (triple negative)\n* Radiology findings: Unifocal disease visible on ultrasound\n\nExclusion Criteria:\n\n* Additional primary cancer\n* Inflammatory breast cancer\n* History of autoimmune disease\n* History of chronic immunosuppression\n* Prior immunotherapy\n* Recent vaccination (within 4 wks.)\n* Prior radiation therapy\n* Prior investigational agent therapy within last 1 year\n* Pregnancy at the time of diagnosis and/ or treatment\n* Breast feeding",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}